Inspira Technologies Oxy B.H.N. Ltd. (IINN)
Inspira Technologies Oxy B.H.N. Ltd. is a medical device company focused on developing the ART system, a minimally invasive alternative to mechanical ventilation. The company aims to address respiratory failure with its innovative blood oxygenation technology.
Company Overview
Inspira Technologies pioneers a new era in respiratory care with its ART system, offering a less invasive alternative to mechanical ventilation, targeting a multi-billion dollar market and positioning itself as a disruptor in critical care.
Investment Thesis
Inspira Technologies presents a compelling investment opportunity within the medical device sector, driven by its innovative ART system and the potential to disrupt the mechanical ventilation market. The ART system addresses a critical unmet need for a less invasive alternative to traditional MV, potentially reducing complications and improving patient outcomes. With a market capitalization of $0.02 billion, Inspira offers significant upside potential as it progresses through regulatory approvals and commercialization. Key value drivers include successful clinical trials, strategic partnerships, and market adoption of the ART system. Upcoming catalysts include regulatory submissions and approvals, which could significantly boost investor confidence and drive stock appreciation. The company's focus on a large and growing market, combined with its innovative technology, positions it for substantial growth in the coming years.
Key Highlights
- Inspira Technologies focuses on developing respiratory support technology as an alternative to invasive mechanical ventilation.
- The ART system, Inspira's lead product, utilizes a minimally invasive dual lumen cannula for direct blood oxygenation.
- The company rebranded from Insense Medical Ltd. to Inspira Technologies Oxy B.H.N. Ltd. in July 2020, reflecting its focus on oxygenation technologies.
- Inspira Technologies has a market capitalization of $0.02 billion.
- Inspira Technologies has a negative P/E ratio of -2.99, reflecting its current stage of development and investment in R&D.
Competitors
Strengths
- Innovative ART system technology.
- Minimally invasive approach.
- Potential to reduce complications associated with mechanical ventilation.
- Focus on a large and growing market.
Weaknesses
- Limited commercialization experience.
- Reliance on regulatory approvals.
- Small company size and limited resources.
- Negative profit margin of -2213.8%
Catalysts
- Upcoming: FDA approval of the ART system in the United States.
- Upcoming: Completion of clinical trials demonstrating the efficacy and safety of the ART system.
- Ongoing: Strategic partnerships with hospital systems to implement and evaluate the ART system.
- Ongoing: Expansion into new geographic markets.
Risks
- Potential: Failure to obtain regulatory approvals for the ART system.
- Potential: Competition from established medical device companies with greater resources.
- Potential: Reimbursement challenges and limited insurance coverage for the ART system.
- Ongoing: The company's negative profit margin of -2213.8% indicates financial instability.
- Ongoing: Dependence on a single product, the ART system, concentrates business risk.
Growth Opportunities
- Expansion into the United States Market: Obtaining FDA approval for the ART system in the United States represents a significant growth opportunity for Inspira Technologies. The US is the largest medical device market globally, and successful entry could drive substantial revenue growth. The timeline for FDA approval is estimated at 1-3 years, and the potential market size for ART in the US could reach hundreds of millions of dollars annually, assuming successful market penetration and adoption by hospitals and healthcare providers.
- Strategic Partnerships with Hospital Systems: Collaborating with leading hospital systems to implement and evaluate the ART system can accelerate market adoption and generate valuable clinical data. These partnerships can provide access to a large patient base and facilitate the integration of ART into standard clinical practice. The timeline for establishing strategic partnerships is ongoing, and the potential impact on revenue and market share is significant, as it can lead to widespread adoption of the ART system.
- Development of Next-Generation ART System: Investing in research and development to enhance the ART system's capabilities and expand its applications can create a sustainable competitive advantage. This could involve improving the system's portability, ease of use, and effectiveness in treating various respiratory conditions. The timeline for developing next-generation ART systems is estimated at 2-4 years, and the potential market impact is substantial, as it can solidify Inspira Technologies' position as a leader in respiratory care technology.
- Expansion into Emerging Markets: Targeting emerging markets with a high prevalence of respiratory diseases and limited access to advanced medical technologies can unlock new growth opportunities. These markets often have less stringent regulatory requirements and lower barriers to entry, making them attractive for early commercialization of the ART system. The timeline for expanding into emerging markets is estimated at 1-2 years, and the potential market size is significant, as these regions represent a large and underserved patient population.
- Licensing and Distribution Agreements: Establishing licensing and distribution agreements with established medical device companies can expand Inspira Technologies' reach and accelerate market penetration. These agreements can leverage the existing sales and marketing infrastructure of larger companies, reducing the need for Inspira Technologies to build its own commercial operations from scratch. The timeline for establishing licensing and distribution agreements is ongoing, and the potential impact on revenue and market share is substantial, as it can provide access to a wider customer base and accelerate market adoption of the ART system.
Opportunities
- FDA approval in the United States.
- Strategic partnerships with hospital systems.
- Expansion into emerging markets.
- Development of next-generation ART system.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and delays.
- Reimbursement challenges.
- Potential for technological obsolescence.
Competitive Advantages
- Proprietary ART system technology with patent protection.
- First-mover advantage in the minimally invasive respiratory support market.
- Potential for strong brand recognition and reputation for innovation.
- High switching costs for hospitals once ART system is integrated into their workflow.
About
Inspira Technologies Oxy B.H.N. Ltd., incorporated in 2018 and based in Ra'annana, Israel, is a specialty medical device company dedicated to the research, development, manufacture, and marketing of innovative respiratory support technology. The company's primary focus is on providing an alternative to invasive mechanical ventilation (MV) for patients suffering from respiratory failure. Recognizing the limitations and potential complications associated with traditional MV, Inspira Technologies has developed the augmented respiration technology system (ART). This system represents a significant advancement in respiratory care, utilizing a minimally invasive, portable dual lumen cannula inserted into the jugular vein. The ART system employs extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels, offering a potentially safer and more comfortable treatment option for patients in critical care. Formerly known as Insense Medical Ltd., the company rebranded to Inspira Technologies Oxy B.H.N. Ltd. in July 2020, reflecting its sharpened focus on oxygenation technologies. With a team of 37 employees, Inspira Technologies is striving to revolutionize the treatment of respiratory failure and improve patient outcomes worldwide.
What They Do
- Develops the ART system, a respiratory support technology.
- Offers an alternative to invasive mechanical ventilation.
- Manufactures minimally invasive, portable dual lumen cannulas.
- Utilizes extra-corporeal direct blood oxygenation.
- Aims to elevate and stabilize declining oxygen saturation levels.
- Researches and markets respiratory support solutions.
Business Model
- Develop and sell the ART system to hospitals and medical centers.
- Generate revenue through the sale of disposable components used with the ART system.
- Establish strategic partnerships and licensing agreements to expand market reach.
Industry Context
Inspira Technologies operates within the medical device industry, specifically targeting the respiratory care market. The global respiratory care devices market is experiencing growth, driven by an aging population, increasing prevalence of respiratory diseases, and technological advancements. Inspira Technologies aims to capture a share of this market by offering a less invasive alternative to traditional mechanical ventilation. Competitors include companies like COSM, ENLV, FEMY, IRIX, and LSTA, which offer various respiratory support solutions. Inspira Technologies differentiates itself through its minimally invasive ART system, which has the potential to reduce complications and improve patient outcomes compared to traditional MV.
Key Customers
- Hospitals and intensive care units (ICUs).
- Medical centers and respiratory care facilities.
- Patients suffering from respiratory failure.
Financials
Chart & Info
Price Chart
Inspira Technologies Oxy B.H.N. Ltd. (IINN) stock price: $0.99 (+0.07, +7.76%)
Why Bull
- •Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in upcoming growth.
- •Community sentiment has shifted positively, with discussions highlighting the potential of their innovative oxygen therapy technology.
- •Analysts are noting increased interest from healthcare sectors, which could lead to expanded partnerships and market reach.
- •Recent product developments and clinical trials have garnered attention, indicating that the company is on a promising path towards commercialization.
Why Bear
- •Concerns about the competitive landscape remain, as larger companies might overshadow Inspira's market entry with established products.
- •Some community members express skepticism about the scalability of their technology, fearing operational challenges ahead.
- •Recent news has highlighted regulatory hurdles that could delay product launches, impacting investor sentiment negatively.
- •Market perception is cautious, with some analysts warning that the company's financial health needs close monitoring amid ongoing development costs.
Latest News
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Feb 9, 2026
Technical Analysis
Rationale
AI-generated technical analysis for IINN including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Inspira Technologies Oxy B.H.N. Ltd. (IINN) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for IINN.
Make a Prediction
Set your price target for Inspira Technologies Oxy B.H.N. Ltd. (IINN), choose a timeframe, and track your prediction accuracy.
Current price: $0.99
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IINN.
Price Targets
Wall Street price target analysis for IINN.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 3/100
Gross margin of 0.7% is below average, suggesting thin margins and potential pricing pressure.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates IINN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Inspira Technologies Oxy B.H.N. Ltd. do?
Inspira Technologies is a medical device company specializing in respiratory support technology. Its primary product is the augmented respiration technology system (ART), a minimally invasive alternative to traditional mechanical ventilation. The ART system utilizes a dual lumen cannula inserted into the jugular vein to provide direct blood oxygenation, aiming to stabilize declining oxygen saturation levels in patients suffering from respiratory failure. Inspira Technologies focuses on researching, developing, manufacturing, and marketing this innovative technology to improve patient outcomes and reduce the complications associated with invasive ventilation.
Is IINN stock a good buy?
IINN stock presents a high-risk, high-reward investment opportunity. The company's innovative ART system has the potential to disrupt the mechanical ventilation market, but it faces significant regulatory and commercialization hurdles. With a negative P/E ratio and a small market cap, IINN is currently a speculative investment. Positive clinical trial results, FDA approval, and successful market adoption of the ART system could drive significant stock appreciation. However, investors should be aware of the risks associated with investing in a small, early-stage medical device company.
What are the main risks for IINN?
The main risks for Inspira Technologies include regulatory hurdles, competition, and financial instability. The company's success depends on obtaining regulatory approvals for the ART system, which is not guaranteed. Inspira Technologies also faces competition from established medical device companies with greater resources and market presence. Furthermore, the company's negative profit margin and limited commercialization experience raise concerns about its financial sustainability. Any delays in regulatory approvals, setbacks in clinical trials, or failure to achieve market adoption could negatively impact the company's stock price.
Is IINN a good stock to buy?
Whether IINN is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the IINN MoonshotScore?
The MoonshotScore for IINN is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is IINN data updated?
IINN stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to IINN is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for IINN?
Growth catalysts for Inspira Technologies Oxy B.H.N. Ltd. (IINN) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Inspira Technologies Oxy B.H.N. Ltd.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are IINN's main competitors?
Inspira Technologies Oxy B.H.N. Ltd. (IINN) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether IINN has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about IINN?
Wall Street analyst coverage for IINN includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is IINN's market cap?
Market capitalization (market cap) for IINN is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows IINN's current market cap alongside enterprise value and other valuation metrics.
How has IINN stock performed recently?
IINN's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing IINN's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in IINN?
Key risk categories for IINN include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures IINN's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling IINN?
Insider trading activity for IINN tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is IINN a good stock for beginners?
Inspira Technologies Oxy B.H.N. Ltd. (IINN) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is IINN for first-time investors?
Every stock carries risk, including Inspira Technologies Oxy B.H.N. Ltd. (IINN). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like IINN.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and due diligence.